Opposing effects of Elk-1 multisite phosphorylation shape its response to ERK activation

Anastasia Mylona,1* Francois Xavier Theillet,2† Charles Foster,1 Tammy M. Cheng,3 Francesc Miralles,1,4 Paul A. Bates,3 Philipp Selenko,3 Richard Treisman1‡

Multisite phosphorylation regulates many transcription factors, including the serum response factor partner Elk-1. Phosphorylation of the transcriptional activation domain (TAD) of Elk-1 by the protein kinase ERK at multiple sites potentiates recruitment of the Mediator transcriptional coactivator complex and transcriptional activation, but the roles of individual phosphorylation events had remained unclear. Using time-resolved nuclear magnetic resonance spectroscopy, we found that ERK2 phosphorylation proceeds at markedly different rates at eight TAD sites in vitro, which we classified as fast, intermediate, and slow. Mutagenesis experiments showed that phosphorylation of fast and intermediate sites promoted Mediator interaction and transcriptional activation, whereas modification of slow sites counteracted both functions, thereby limiting Elk-1 output. Progressive Elk-1 phosphorylation thus ensures a self-limiting response to ERK activation, which occurs independently of antagonizing phosphatase activity.

Multisite protein phosphorylation increases the complexity of functional signaling outputs that can be generated from single protein kinase inputs. It can set thresholds for activity or transform graded signals into switch-like responses (1–4). Many transcription factors and their interacting regulatory proteins are subject to multisite phosphorylation, which allows distinct aspects of protein function, including protein turnover, nuclear import and export, and specific protein interactions to be controlled independently (5). However, in general, the dynamics and functional roles of individual phosphorylation events are incompletely understood.

The ternary complex factor (TCF) subfamily of Ets domain transcription factors, consisting of Elk 1, SAP 1, and Net, provides an example of multisite phosphorylation in transcriptional activation. TCFs, together with their partner protein SRF, function in many biological processes by coupling SRF target genes to mitogen activated protein kinase (MAP kinase) signaling (5). Mitogenic and stress stimuli induce phosphorylation of TCF C-terminal activation domains (TADs) at multiple S/T P (Ser or Thr Pro) phosphorylation sequences, of which eight are conserved across the family (Fig. 1A and fig. S1 (6–11)). Two MAP kinase docking sites, the D box and the Phe Gln Phe Pro (FQFP) motif, control phosphorylation of these sites (12–15). Multisite phosphorylation triggers transcriptional activation by TCFs, facilitating their interaction with the Mediator transcriptional coactivator complex (16–19), but the kinetics with which the different sites are phosphorylated, and whether they serve distinct functions, remain unclear.

To obtain atomic resolution insights into phosphorylation of the Elk 1 TAD, we used nuclear magnetic resonance (NMR) spectroscopy (20) to monitor its modification by recombinant ERK2 in vitro (Fig. 1B and fig. S2A). Time-resolved NMR experiments revealed that each phosphorylation proceeded efficiently but at markedly different rates. Phosphorylation of Thr369 and Ser384, which flank the central Phe Trp (FW) motif implicated in Mediator interaction (18), occurred faster than...

---

**Fig. 1. Multisite phosphorylation of Elk-1 TAD.** (A) Linear outline of Elk-1 fast (red), intermediate (blue), and slow (yellow) S/T-P phosphorylation sites. Kinase docking motifs are shown in green; the FW residues (purple) are essential for Mediator association. (B) NMR analysis of Elk-1 TAD (amino acids 309 to 429) phosphorylation with recombinant ERK2. Left: 2D 1H,15N NMR spectrum of unphosphorylated Elk-1 (black), with phosphorylation site signals color-coded as in (A). Right: Overlay of 2D NMR spectra of phosphorylated [gray and color-coded as in (A)] and unmodified Elk-1 (black). (C) Time-resolved modification curves of individual Elk-1 sites upon phosphorylation with ERK2; error bars denote differences between replicate experiments on two independent samples. (D) Time-course Western blot of GST–Elk-1 TAD phosphorylation and phosphorylation site-specific antibody detection.

---

*Corresponding author. Email: richard.treisman@crick.ac.uk

‡Present address: AM, Faculty of Life Sciences & Medicine, Guy’s Campus, Kings’ College London, London SE1 1UL, UK. (Present address: F XT, Institute of Integrative Biology of the Cell (I2BC), CNRS/CEA/Paris Saclay University, 91191 Gif sur Yvette, France.

†Corresponding author. Email: richard.treisman@crick.ac.uk

‡Signalling and Transcription Laboratory, Francis Crick Institute, Lincoln’s Inn Fields Laboratory, London WC2A 3LY, UK. †In Cell NMR Laboratory, Department of NMR Supported Structural Biology, Leibniz Institute of Molecular Pharmacology (FMP Berlin), Berlin, Germany. Biomolecular Modelling Laboratory, Francis Crick Institute, Lincoln’s Inn Fields Laboratory, London WC2A 3LY, UK. Molecular & Clinical Sciences Research Institute, St. George’s, University of London, London SW17 0RE, UK.

*Present address: AM, Faculty of Life Sciences & Medicine, Guy’s Campus, Kings’ College London, London SE1 1UL, UK. (Present address: F XT, Institute of Integrative Biology of the Cell (I2BC), CNRS/CEA/Paris Saclay University, 91191 Gif sur Yvette, France.

‡Corresponding author. Email: richard.treisman@crick.ac.uk
modification of Thr\textsuperscript{354}, Thr\textsuperscript{364}, and Ser\textsuperscript{390}, whereas residues Thr\textsuperscript{357}, Ser\textsuperscript{363}, and Thr\textsuperscript{357} were modified more slowly (Fig. 1C), which we confirmed by immunoblotting (Fig. 1D). Chemical shift analysis (Co, C3) showed no stable secondary structure elements in unmodified or phosphorylated Elk 1 TAD (Fig. S2B).

As a first step toward understanding the basis for the phosphorylation sites' differential kinetic behavior, we devised a reaction model based on Michaelis Menten enzyme kinetics. To simplify the mathematical treatment, we grouped Elk 1 sites into three classes: fast (Thr\textsuperscript{359} and Ser\textsuperscript{384}), intermediate (Thr\textsuperscript{354}, Thr\textsuperscript{364}, and Ser\textsuperscript{390}), and slow (Thr\textsuperscript{337}, Thr\textsuperscript{357}, and Ser\textsuperscript{363}). We assumed that ERK2 phosphorylation is distributive, that enzymatic rate constants ($k_{\text{cat}}$) are similar for all sites, and that the different sites have relative affinities for ERK2 modeled by increasing Michaelis Menten constants ($K_{M_{\text{Fast}}} < K_{M_{\text{Int}} < K_{M_{\text{Slow}}}}$) (Fig. 2A and fig. S3A) (20). This model, which recapitulated the measured kinetics of in vitro Elk 1 phosphorylation well (Fig. 2B), predicted that removal of fast or intermediate sites should increase the phosphorylation rates of other sites. To test this idea, we analyzed the phosphorylation kinetics of Elk 1 TAD mutants in which we substituted all fast or intermediate phosphoryoceptor residues with alanines (Elk 1F: Thr\textsuperscript{359} → Ala, Ser\textsuperscript{384} → Ala; Elk 1I: Thr\textsuperscript{354} → Ala, Thr\textsuperscript{364} → Ala, Ser\textsuperscript{390} → Ala) (Fig. 2A). In the fast site mutant Elk 1F, phosphorylation rates of intermediate and slow sites increased, whereas those of the fast and slow sites increased in the intermediate site mutant Elk 1I; in both cases, the altered kinetics fit well with those predicted by the model (Fig. 2B and fig. S3B). Thus, even the fast sites are not phosphorylated at the maximum possible rate in the wild type protein. Moreover, phosphorylation of an Elk 1 TAD mutant in which Thr\textsuperscript{359} and Ser\textsuperscript{384} were replaced with aspartates was similar to Elk 1F, excluding the possibility that fast site phosphorylation primes later modification events (Fig. S3B).

To gain more insight into the factors affecting individual sites' phosphorylation kinetics, we assayed the role played by primary sequence. To do this, we exchanged the sequences surrounding the fast Thr\textsuperscript{359} and slow Ser\textsuperscript{390} sites. This also effectively changed their reactivities, which suggested that these sites' phosphorylation rates reflect their position relative to ERK docking sequences, rather than intrinsic differences in reactivity (Fig. 2C). We therefore examined the contributions of the D box and FQFP ERK docking motifs to each site's phosphorylation kinetics. Deletion of the D box decreased the rates of Thr\textsuperscript{337}, Thr\textsuperscript{354}, Thr\textsuperscript{364}, and Thr\textsuperscript{359} phosphorylation but increased the rates of Ser\textsuperscript{390}, Thr\textsuperscript{357}, and Ser\textsuperscript{363} modification (Fig. 2D). In contrast, deletion of the FQFP motif decreased the rate of Ser\textsuperscript{390} phosphorylation but enhanced modification of intermediate sites, including adjacent Ser\textsuperscript{390}, with no effect on the C terminal sites (Fig. 2D). Thus, the ERK docking motifs differentially affect each phosphorylation site's competitive behavior. Previous studies showed that Elk 1 TAD phosphorylation by JNK and p38 MAP kinases differs from phosphorylation by ERK (10, 21, 24) and that this reflects differences in their docking interactions (12, 14, 15, 25). In deed, these kinases exhibited site preferences and phosphorylation rates that were distinct from that of ERK2 (Fig. S3C). Taken together,
our results show that the different rates of Elk 1 TAD phosphorylation by ERK2 follow a competitive mechanism that is governed by the position of individual Elk 1 substrate sites relative to ERK2 docking interactions.

To test whether the different kinetic classes of Elk 1 TAD phosphorylation sites are functionally equivalent, we expressed Elk 1 mutants in fibroblasts derived from TCF deficient (Elk1−/−; Elk3−/−; Elk4−/−) triple knockout mouse embryos (TKO MEFs; fig. S4, A to C). In these cells, immediate early (IE) gene transcription is defective, but expression of wild type mouse Elk 1 restored the IE transcriptional activation seen in wild type MEFs after activation of ERK by treatment with TPA (12-O-tetradecanoylphorbol 13-acetate) (fig. S4D). As expected, alanine substitutions of fast and/or intermediate sites, or of the FW motif, greatly diminished or abolished the ability of Elk 1 to activate TCF SRF target gene transcription after TPA stimulation (Fig. 3A). Surprisingly, however, mutation of the slow sites substantially enhanced Elk 1 mediated activation of TCF SRF target genes (Fig. 3A). Alanine substitutions at individual slow sites also increased Elk 1 activity, with Thr418 exhibiting the greatest effect (Fig. 3B and fig. S4, E to G). TCF SRF signaling is important for cellular proliferation (26, 27), and TKO MEFs proliferated more slowly than wild type MEFs. The reconstituted TKO MEFs exhibited enhanced proliferation rates, which correlated with the ability of each mutant to promote transcriptional activation (Fig. 3C).

Phosphorylation of Elk 1 promotes transcriptional activation by facilitating its MED23 dependent interaction with the Mediator complex (16–18). We therefore investigated whether the different transcriptional activities of the Elk 1 mutants reflected alterations in Mediator binding. We prepared extracts of TKO cells expressing wild type or mutant Elk 1 proteins and assessed Elk 1 association with Mediator by communoprecipitation of the MED23, MED24, and MED16 subunits. Consistent with the transcription experiments, Elk 1 Mediator interaction was induced by TPA stimulation and dependent on the FW motif; it was abolished by alanine substitutions of fast and intermediate sites, and increased in the slow site Elk 1 mutant (Fig. 3D). We obtained similar results when we used glutathione S-transferase (GST) Elk 1 TAD proteins to recover Mediator proteins from unstimulated NIH3T3 cell extracts (Fig. 3E). In this assay, ERK2 phosphorylation time course experiments showed that Mediator recovery by the wild type Elk 1 TAD was most efficient prior to modifications of the slow sites (fig. S5, A and B). Taken together, these data show that according to the sites involved, ERK2 phosphorylation promotes or inhibits transcriptional activation by Elk 1, which reflects alterations in Elk 1 Mediator interactions.

Next, we investigated Elk 1 TAD phosphorylation kinetics in vivo. Previous studies were unable to distinguish the progressive phosphorylation of fast and slow Elk 1 sites (6). However, by incubating cells at 25°C to slow down reactions, we confirmed that phosphorylation rates can be ranked in the order Ser264 > Thr364 > Thr418 and that different site classes exhibited a similar competitive behavior, as seen in vitro (fig. S6A). Reasoning that phosphorylation of the Elk 1 TAD might be sensitive to kinetic effects at limiting signal strengths, we titrated ERK activity using
increasing amounts of TPA. This both increased the maximal extent of ERK activation and advanced the time at which it occurred (Fig. 4B), resulting in prolonged Egr1 mRNA accumulation (Fig. 4C). Thus, progressive phosphorylation of the Elk 1 TAD by a single kinase, ERK, attenuates the transcriptional response of Elk 1, shaping it according to the strength and kinetics of ERK activation.

Our results show that phosphorylation of the Elk 1 TAD by ERK can either promote or inhibit Mediator interaction depending on the sites inolved, thereby modulating transcriptional activation. Given that the TAD sequences are conserved in the other TCFs, our findings may also apply to them. The more rapidly phosphorylated sites are located in the substantially conserved central core of the TAD and are essential for transcriptional activation, lying close to the FW hydrophobic motif required for Elk 1 Mediator interaction (10, 18). Multisite phosphorylation of these residues might stabilize the interaction and perhaps also set a signaling threshold for it, similar to the way that multisite phosphorylation sets a threshold for the Sic 1 Cdc4 interaction (29). In contrast, slowly phosphorylated sites located in N and C terminal of the conserved TAD core act negatively. Their phosphorylation inhibits Mediator recruitment and limits transcriptional activation (Fig. 4D) and may also facilitate recruitment of negative regulators of Elk 1 activity. Together, these properties ensure that ERK phosphorylation of the Elk 1 TAD is self-limiting, whereby phosphorylation of slow sites attenuates TCF SRF target gene expression under conditions of strong or sustained ERK signaling (Fig. 4D). Our results challenge the common assumption that multisite modification events act unidirectionally and can only be reversed or limited by antagonistic enzymes, such as phosphatases. Given the prevalence of such events in different biological processes, we expect that similar mechanisms may govern other regulatory interactions.

**REFERENCES AND NOTES**

VACCINES

Rapid development of a DNA vaccine for Zika virus

Kimberly A. Dowd,1 Sung Youl Ko,2* Kaitlyn M. Morabito,2 Eun Sung Yang,2 Rebecca S. Pecel,1 Christina R. DeMaso,1 Leda R. Castilho,2,3 Peter Abbink,4 Michael Boyd,4 Ramya Nityanandam,4 David N. Gordon,1 John Robert Gallagher,5 John Paul Todd,2 Yaroslav Tsybovsky,6 Audray Harris,5 John R. Mascola,2 Theodore C. Pierson,1 Martha C. Nason,11 Dan H. Barouch,4 Mario Roederer,2 Wing Pui Kong,2 Mark G. Lewis,8 Rafael De La Barrera,9 Kenneth H. Eckels,9 Richard G. Jarman,10 Yan Jang S. Huang,7 Stephen Higgs,7 Dana L. Vanlandingham,7 Hanne Andersen,8 Xuejun Chen,2 John Paul Todd,2 Yaroslav Tsybovsky,6 Andray Harris,5 Yan Jang S. Huang,7 Stephen Higgs,7 Dana L. Vanlandingham,7 Hanne Andersen,8 Mark G. Lewis,8 Rafael De La Barrera,9 Kenneth H. Eckels,9 Richard G. Jarman,10 Martha C. Nason,11 Dan H. Barouch,4 Mario Roederer,2 Wing Pui Kong,2 John R. Mascola,2 Theodore C. Pierson,1 Barney S. Graham2†

Zika virus (ZIKV) was identified as a cause of congenital disease during the explosive outbreak in the Americas and Caribbean that began in 2015. Because of the ongoing fetal risk from endemic disease and travel-related exposures, a vaccine to prevent viremia in women of childbearing age and their partners is imperative. We found that vaccination with DNA expressing the premembrane and envelope proteins of ZIKV was immunogenic in mice and nonhuman primates, and protection against viremia after ZIKV challenge correlated with serum neutralizing activity. These data not only indicate that DNA vaccination could be a successful approach to protect against ZIKV infection, but also suggest a protective threshold of vaccine-induced neutralizing activity that prevents viremia after acute infection.

The emergence of Zika virus (ZIKV) in the Americas and Caribbean follows a series of global threats to public health from mosquito borne viral diseases over the past three decades. Because of the profound impact on individuals and society from a disabling congenital disease caused by ZIKV infection in pregnant women, the World Health Organization declared ZIKV a global health emergency in February 2016. Although it is likely that the incidence of ZIKV infection will decline considerably within 1 to 2 years (1), it is also likely that ZIKV will become endemic in tropical and sub tropical regions, with sporadic outbreaks and potential for spread into new geographical areas, as observed with other emerging arboviruses such as West Nile (WNV) and chikungunya. Therefore, unless immunity is established before childbearing age, pregnant women will continue to be at risk for an infection that could harm their fetus. Further, because men can harbor ZIKV in semen for several months after a clinically unapparent infection and can sexually transmit virus to a pregnant partner (2), even women in nonendemic regions will have some ongoing risk if exposed to men who have traveled to endemic regions. These characteristic features of transmission and disease suggest that there will be an ongoing need for a ZIKV vaccine to maintain a high level of immunity in the general population and in travelers to endemic regions to reduce the frequency of fetal infection. To rapidly address the critical need for a preservative vaccine to curtail the ongoing ZIKV outbreak in the Americas, we chose a gene based vaccine delivery approach that leverages our prior experience with a DNA based WNV vaccine (3). Advantages of DNA vaccines include the ability to rapidly test multiple candidate antigen designs, the ability to rapidly produce material that conforms to good manufacturing practices, an established safety profile in humans, and a relatively straightforward regulatory pathway into clinical evaluation.

Antigen design was guided by prior knowledge about humoral immunity to flaviviruses. Vaccine elicited neutralizing antibodies (NAbs) are associated with protection from flavivirus mediated disease (4). Because the most potent monoclonal flavivirus NAbs map to conformational epitopes in domain III (DIII) of the envelope (E) protein (5), or to more complex quaternary epitopes that bridge between antiparallel E dimers or between dimer rafts arrayed on the virus surface (6, 7), our goal was to identify constructs that produced particles that faithfully captured the antigenic complexity of infectious virions. Expression of the structural proteins premembrane (prM) and E are sufficient for the production and release of virus like subviral particles (SVPs) with antigenic and functional properties similar to those of infectious virions (8, 9).

To identify promising vaccine candidates, prM E constructs were synthesized and screened for expression and efficiency of particle release from transfected cells. prM E sequences were inserted into a cytomegalovirus immediate early promoter containing vector (VRC8400) that has been evaluated clinically in several previous studies (3, 10, 11). These constructs are distinct from one reported in recent studies by Larocca et al. (12) and Abbink et al. (13) that was based on a Brazilian isolate (strain

*These authors contributed equally to this work. †Corresponding author. Email: pierson@niaid.nih.gov (T.C.P.); bgraham@mail.nih.gov (B.S.G.)

1Viral Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. 2Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. 3Federal University of Rio de Janeiro, COPPE (Instituto Alberto Luiz Coimbra de Pós Graduação e Pesquisa de Engenharia), Chemical Engineering Program, Rio de Janeiro, Rio de Janeiro, Brazil. 4Center for Viral and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. 5Structural Informatics Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. 6Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA. 7Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA. 8Bioqual, Rockville, MD 20852, USA. 9Translational Medicine Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA. 10Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA. 11Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.